El objetivo principal fueron las diferencias en los valores de hemoglobina glucosilada (HbA1c) entre ambos grupos. autodeterminación de la glucemia capilar (AGC).
MétodoĮstudio de cohortes de 24 semanas de duración de sujetos con DM1 tratados con ISCI expuestos (1:1) a monitorización Flash de glucosa intersticial vs. Randomized controlled trials are needed to assess the effectiveness of this system in CSII-treated T1DM patients.Īnalizar el efecto clínico de la monitorización Flash de glucosa intersticial en pacientes con diabetes mellitus tipo 1 (DM1) tratados con infusión subcutánea continúa de insulina (ISCI). The Flash glucose monitoring system is a novel approach to improve blood glucose control in CSII-treated T1DM patients. No safety issues related to Flash use were recorded. In fact, the Flash cohort showed a three-fold increase in daily self-monitoring of glucose, while daily frequency of SMBG decreased during the study (−1.8 tests/24 h (95% CI −3, −0.7 p = 0.01). Flash patients captured 93.9% of data through 17.8 ± 9.9 scans daily. Only the Flash group showed a significant decrease in HbA1c levels of −0.4% (95% CI, −0.6, −0.2 p = 0.004) during follow-up. At the end of the study, mean HbA1c levels improved in patients in the Flash group (7.1 ± 0.7 vs. Thirty-six patients with a mean age of 38.2 years (range 22–55) and a mean T1DM duration of 20.9 ± 7.8 years, treated with CSII for 7.1 ± 5.4 years, were enrolled into the study.
The primary outcome was the difference in hemoglobin A1c (HbA1c) levels between both groups at the end of the study. self-monitoring of capillary blood glucose (SMBG). MethodsĪ 24-week retrospective cohort study in CSII-treated T1DM patients exposed (1:1) to the Flash glucose monitoring system vs. To analyze the clinical impact of the Flash glucose monitoring system in patients with type 1 diabetes mellitus (T1DM) treated with continuous subcutaneous insulin infusion (CSII).
0 kommentar(er)
